2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Olaparib-abiraterone combo improves PFS in mCRPC

Roshini Claire Anthony, 20220316160001

The combination of olaparib and abiraterone in the first-line setting improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the phase III PROpel trial showed.

Lenvatinib + pembrolizumab improves PFS in East Asian patients with advanced RCC

Elaine Soliven, 20220315000000

Lenvatinib + pembrolizumab combination regimen improves progression-free survival (PFS) compared with sunitinib in a subset of East Asian patients with advanced renal cell carcinoma (aRCC), a finding that was similar to that of the global population of the CLEAR* trial, according to a subanalysis presented at ASCO GU 2022.

OS benefit of first-line NIVO + IPI holds out through 5 years over sunitinib in sarcomatoid RCC

OS benefit of NIVO + IPI holds out through 5 years over sunitinib in sarcomatoid RCC

Pearl Toh, 20220310140100

First-line treatment with a combination of nivolumab plus ipilimumab (NIVO + IPI) continues to show long-term survival benefits over sunitinib out to 5 years in patients with advanced clear-cell renal carcinoma (RCC) with sarcomatoid features, according to the CheckMate 214 study presented at GUCS 2022.

Continuing enzalutamide after progression improves PFS in mCRPC

Roshini Claire Anthony, 20220309180001

In patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression while on enzalutamide treatment, continuing enzalutamide appears to improve progression-free survival (PFS), according to results of the phase IIIb PRESIDE trial.

Triplet therapy with darolutamide a potential new standard of care for mHSPC

Darolutamide add-on: A new standard of care for metastatic prostate cancer?

Pearl Toh, 20220306140100

Adding darolutamide to androgen-deprivation therapy (ADT) plus docetaxel significantly increases overall survival (OS) in patients with metastatic, hormone-sensitive prostate cancer (mHSPC), according to the ARASENS* trial presented at the ASCO GUCS 2022.

Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC

Roshini Claire Anthony, 20220304180001

In patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations*, combining niraparib with abiraterone acetate plus prednisone (AAP) in the first-line setting improved radiographic progression-free survival (rPFS) and other outcomes, results of the phase III MAGNITUDE study showed.

High-dose ipilimumab augments nivolumab benefit for TCC

Audrey Abella, 20220301080213

In the phase II TITAN-TCC* trial presented at ASCO GU 2022, the addition of ipilimumab to nivolumab led to improved responses in patients with pretreated (second/third line) advanced/metastatic or surgically unresectable transitional cell carcinoma (TCC).

Avelumab continues to show promise for bladder cancer

Audrey Abella, 20220228151720

In individuals with advanced urothelial carcinoma (UC), a first-line maintenance treatment regimen comprising a combination of avelumab and best supportive care (BSC) provided better survival benefit than BSC alone, according to long-term and subgroup analyses of the phase III JAVELIN Bladder 100 trial presented at ASCO GU 2022.